Browsing by Author "Gendron, Tania"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Clinical and neuropathological associations of plasma Aβ42/Aβ40, p‐tau217 and neurofilament light in sporadic frontotemporal dementia spectrum disorders
    (Wiley, 2025-01-29) Rajbanshi, Binita; Araujo, Igor Prufer Q. C.; VandeVrede, Lawren; Ljubenkov, Peter A.; Staffaroni, Adam M.; Heuer, Hilary W.; Lago, Argentina Lario; Ramos, Eliana Marisa; Petrucelli, Leonard; Gendron, Tania; Dage, Jeffrey L.; Seeley, William W.; Grinberg, Lea T.; Spina, Salvatore; Bateman, Randall J.; Rosen, Howard J.; Boeve, Bradley F.; Boxer, Adam L.; Rojas, Julio C.; ALLFTD Consortium; Neurology, School of Medicine
    Introduction: Plasma amyloid beta42/amyloid beta40 (Aβ42/Aβ40) and phosphorylated tau217 (p-tau217) identify individuals with primary Alzheimer's disease (AD). They may detect AD co-pathology in the setting of other primary neurodegenerative diseases, but this has not been systematically studied. Methods: We compared the clinical, neuroimaging, and neuropathological associations of plasma Aβ42/Aβ40 (mass spectrometry), p-tau217 (electrochemiluminescence), and neurofilament light ([NfL], single molecule array [Simoa]), as markers of AD co-pathology, in a sporadic frontotemporal dementia (FTD) cohort (n = 620). Results: Aβ42/Aβ40 showed no clinicopathological associations. High p-tau217 was present in amnestic dementia (AmD) presumed to be due to FTD, logopenic primary progressive aphasia (lvPPA), and APOEε4 carriers, and correlated with worse baseline and longitudinal clinical scores, lower hippocampal volumes, and more severe AD co-pathology (Braak Stage). NfL was elevated in all FTD phenotypes, and correlated with clinical scores and frontotemporal brain volumes. Discussion: Plasma p-tau217 has clinical, neuroimaging, and neuropathological correlates in sporadic FTD and may identify FTD cases with AD co-pathology. Highlights: Alzheimer's disease (AD) features could be identified with plasma phosphorylated tau217 (p-tau217) in frontotemporal lobar degeneration (FTLD).Plasma p-tau217 is a better discriminator of AD co-pathology and AD-associated features in FTLD than plasma amyloid beta42/amyloid beta40 (Aβ42/Aβ40) and neurofilament light (NfL).In FTLD, plasma p-tau217, but not Aβ42/Aβ40 or neurofilament light, has phenotypical, neurocognitive, and neuroimaging correlates suggestive of AD co-pathology.
  • Thumbnail Image
    Item
    Sex differences in the clinical manifestation of autosomal dominant frontotemporal dementia
    (Wiley, 2025) Memel, Molly; Staffaroni, Adam M.; Ilan-Gala, Ignacio; Garcia Castro, Jesús; Kornak, John; Tartaglia, Carmela M.; Saloner, Rowan; VandeBunte, Anna M.; Paolillo, Emily W.; Cadwallader, Claire J.; Chen, Coty; Gorno-Tempini, Maria Luisa; Mandelli, Malu; Apostolova, Liana; Graff-Radford, Neil; Litvan, Irene; Bayram, Ece; Pressman, Peter S.; Miyagawa, Toji; Mackenzie, Ian; Goldman, Jill; Darby, Richard R.; Appleby, Brian S.; Petrucelli, Len; Gendron, Tania; Heuer, Hilary W.; Forseberg, Leah K.; Rojas, Julio C.; Boeve, Brad F.; Brushaber, Nellie; Domoto-Reilly, Kimiko; Ghoshal, Nupur; Lapid, Maria; Pascual, Belen; Lee, Suzee; Ramos, Eliana Marisa; Ramanan, Vijay; Rademakers, Rosa; Rascovsky, Katya; Pantelyat, Alex; Masdeu, Joseph C.; Snyder, Allison; Boxer, Adam L.; Rosen, Howard J.; Casaletto, Kaitlin; ALLFTD Consortium; Neurology, School of Medicine
    Introduction: Sex differences are apparent in neurodegenerative diseases but have not been comprehensively characterized in frontotemporal dementia (FTD). Methods: Participants included 337 adults with autosomal dominant FTD enrolled in the ALLFTD Consortium. Clinical assessments and plasma were collected annually for up to 6 years. Linear mixed-effects models investigated how sex and disease stage are associated with longitudinal trajectories of cognition, function, and neurofilament light chain (NfL). Results: While sex differences were not apparent at asymptomatic stages, females showed more rapid declines across all outcomes in symptomatic stages compared to males. In asymptomatic participants, the association between baseline NfL and clinical trajectories was weaker in females versus males, a difference that was not present in symptomatic participants. Discussion: In genetic FTD, females show cognitive resilience in early disease stages followed by steeper clinical declines later in the disease. Baseline NfL may be a less sensitive prognostic tool for clinical progression in females with FTD-causing mutations. Highlights: Females with genetic FTD exhibit overall steeper increases in plasma neurofilament light chain (NfL) than males. Females with genetic FTD outperform NfL levels in asymptomatic stages compared to males. Once symptomatic, females with genetic FTD decline more rapidly than males. Plasma NfL is a stronger prognostic marker in asymptomatic males than females.